Jacobs Levy Equity Management Inc. Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Jacobs Levy Equity Management Inc. bought a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,236 shares of the biotechnology company’s stock, valued at approximately $119,000.

Several other large investors have also modified their holdings of the stock. Arrowstreet Capital Limited Partnership purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at $9,662,000. JPMorgan Chase & Co. raised its position in Aurinia Pharmaceuticals by 84.4% in the 4th quarter. JPMorgan Chase & Co. now owns 927,298 shares of the biotechnology company’s stock valued at $8,327,000 after purchasing an additional 424,482 shares during the last quarter. Renaissance Technologies LLC raised its position in Aurinia Pharmaceuticals by 44.0% in the 4th quarter. Renaissance Technologies LLC now owns 700,900 shares of the biotechnology company’s stock valued at $6,294,000 after purchasing an additional 214,200 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in Aurinia Pharmaceuticals by 724.4% in the 4th quarter. Cubist Systematic Strategies LLC now owns 168,252 shares of the biotechnology company’s stock valued at $1,511,000 after purchasing an additional 147,843 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Aurinia Pharmaceuticals by 6.9% in the 4th quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock valued at $15,535,000 after purchasing an additional 112,113 shares during the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 27th.

Insider Activity

In other news, insider Greg Keenan sold 12,239 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the completion of the transaction, the insider now owns 161,789 shares in the company, valued at $1,294,312. This trade represents a 7.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Peter Greenleaf sold 195,593 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the transaction, the chief executive officer now owns 1,953,892 shares of the company’s stock, valued at $15,631,136. This represents a 9.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock worth $2,753,094 in the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Aurinia Pharmaceuticals Stock Up 0.5%

Shares of Aurinia Pharmaceuticals stock opened at $8.19 on Monday. The company has a market cap of $1.11 billion, a P/E ratio of -54.60 and a beta of 1.16. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals Inc. has a one year low of $5.11 and a one year high of $10.67. The firm has a fifty day moving average of $8.02 and a two-hundred day moving average of $8.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.08. The company had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. On average, analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.